From owner-freebsd-chat@FreeBSD.ORG Mon May 5 21:59:06 2003 Return-Path: Delivered-To: freebsd-chat@freebsd.org Received: from mx1.FreeBSD.org (mx1.freebsd.org [216.136.204.125]) by hub.freebsd.org (Postfix) with ESMTP id D18C037B401 for ; Mon, 5 May 2003 21:59:06 -0700 (PDT) Received: from stork.mail.pas.earthlink.net (stork.mail.pas.earthlink.net [207.217.120.188]) by mx1.FreeBSD.org (Postfix) with ESMTP id 4CDF643FBD for ; Mon, 5 May 2003 21:59:06 -0700 (PDT) (envelope-from tlambert2@mindspring.com) Received: from pool0018.cvx21-bradley.dialup.earthlink.net ([209.179.192.18] helo=mindspring.com) by stork.mail.pas.earthlink.net with asmtp (SSLv3:RC4-MD5:128) (Exim 3.33 #1) id 19CuXY-0001Rf-00; Mon, 05 May 2003 21:58:56 -0700 Message-ID: <3EB740B8.DF5EE5A6@mindspring.com> Date: Mon, 05 May 2003 21:57:28 -0700 From: Terry Lambert X-Mailer: Mozilla 4.79 [en] (Win98; U) X-Accept-Language: en MIME-Version: 1.0 To: JacobRhoden References: <4.3.2.7.2.20030504213212.03a5f140@localhost> <4.3.2.7.2.20030505082225.03cc5ec0@localhost> <3EB72E3B.1A77D437@mindspring.com> <200305061344.30358.jrhoden@unimelb.edu.au> Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-ELNK-Trace: b1a02af9316fbb217a47c185c03b154d40683398e744b8a40e9e0745e88b2f5ec0a7afc69acbe177350badd9bab72f9c350badd9bab72f9c350badd9bab72f9c cc: chat@freebsd.org Subject: Re: open source license with 24 month proprietary clause X-BeenThere: freebsd-chat@freebsd.org X-Mailman-Version: 2.1.1 Precedence: list List-Id: Non technical items related to the community List-Unsubscribe: , List-Archive: List-Post: List-Help: List-Subscribe: , X-List-Received-Date: Tue, 06 May 2003 04:59:07 -0000 JacobRhoden wrote: > On Tue, 6 May 2003 01:38 pm, Terry Lambert wrote: > > who needs long term treatment with your drug, > > is worth a heck of a lot more long term revenue if you treat them > > instead of curing them. > > That is true, but if you are the researcher working for the drug company, your > motivation is not to make money for your company, you want to be the person > that cured aids (no one remembers the person who helped temporarily alieve > something) So there's a discrepancy between what's being funded and what the researcher wants to have been funded... I don't see the issue... Theo de Raadt might, though, given his recent DARPA funding issue. Have to wonder if the researchers who wanted something else to be funded have had their own funding issues, or if they've just taken their bosses money. 8-). -- Terry